New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles

European Journal of Pharmaceutical Sciences

Volumn 48, Issue 1-2, 2013, Pages 282-290

  Mussi, Samuel Vidal ^a   Silva, Renata Carvalho ^b   Oliveira, Mônica Cristina De ^a   Lucci, Carolina Madeira ^b   Azevedo, Ricardo Bentes De ^b   Ferreira, Lucas Antônio Miranda ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b INSTITUTO DE CIÊNCIAS BIOLÓGICAS   (Brazil)

Author keywords

Cancer; Docosahexaenoic acid; Doxorubicin; Ion pairing; Solid lipid nanoparticles

Indexed keywords

DOCOSAHEXAENOIC ACID; DOXORUBICIN; OCTADECYLAMINE; SOLID LIPID NANOPARTICLE; TRIETHANOLAMINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RELEASE; DRUG SOLUBILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG TUMOR; NANOENCAPSULATION; PARTICLE SIZE; PH; PRIORITY JOURNAL; ZETA POTENTIAL;

1-OCTANOL; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL SURVIVAL; DOCOSAHEXAENOIC ACIDS; DOXORUBICIN; DRUG CARRIERS; HUMANS; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; WATER;

EID: 84870675676     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.10.025     Document Type: Article

References (37)

1. L. Alvarez-Cedrón, M.L. Sayalero, and J.M. Lanao High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues J. Chromatogr. B Biomed. Sci. Appl. 721 1999 271 281
2. P. Bougnoux, N. Hajjaji, M.N. Ferrasson, B. Giraudeau, C. Couet, and O. Le Floch Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial Brit. J. Cancer 101 2009 78 85
3. H. Bunjes Lipid nanoparticles for the delivery of poorly water-soluble drugs J. Pharm. Pharmacol. 62 2010 1637 1645
4. G.A. Castro, A.L.R. Coelho, C.A. Oliveira, G.A.B. Mahecha, R.L. Oréfice, and L.A.M. Ferreira Formation of ion pairing as an alternative to improve encapsulation and stability and to reduce skin irritation of retinoic acid loaded in solid lipid nanoparticles Int. J. Pharm. 381 2009 77 83
5. S. Colas, K. Mahéo, F. Denis, C. Goupille, C. Hoinard, P. Champeroux, F. Tranquart, and P. Bougnoux Sensitization by dietary docosahexaenoic acid of rat mammary carcinoma to anthracycline: a role for tumor vascularization Clin. Cancer Res. 12 2006 5879 5886
6. Z. Darzynkiewicz, S. Bruno, G. Del Bino, W. Gorczyca, M.A. Hotz, P. Lassota, and F. Traganos Features of apoptotic cells measured by flow cytometry Cytometry 13 1992 795 808
7. A. Eckhardt, P. Müller, K.A. Hiller, S. Krifka, C. Bolay, G. Spagnuolo, G. Schmalz, and H. Schweikl Influence of TEGDMA on the mammalian cell cycle in comparison with chemotherapeutic agents Dent. Mater. 26 2009 232 241
8. A. Fundarò, R. Cavalli, A. Bargoni, D. Vighetto, G.P. Zara, and M.R. Gasco Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats Pharmacol. Res. 42 2000 337 343
9. E. Germain, V. Chajès, S. Cognault, C. Lhuillery, and P. Bougnoux Enhancement of doxorubicin cytotoxicity by polyunsaturated fatty acids in the human breast tumor cell line MDA-MB-231: relationship to lipid peroxidation Int. J. Cancer 75 1998 578 583
10. W.E. Hardman, C.P. Avula, G. Fernandes, and I.L. Cameron Three percent dietary fish oil concentrate increased efficacy of doxorubicin against MDA-MB 231 breast cancer xenografts Clin. Cancer Res. 7 2001 2041 2049
11. E. Healy, M. Dempsey, C. Lally, and M.P. Ryan Apoptosis and necrosis: mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line Kidney Int. 54 1998 1955 1966
12. O. Kepp, L. Galluzzi, M. Lipinski, J. Yuan, and G. Kroemer Cell death assays for drug discovery Nat. Rev. Drug Discov. 10 2011 221 237
13. Y. Li, J. Wang, M.G. Wientjes, and J.L. Au Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor Adv. Drug Deliv. Rev. 64 2012 29 39
14. P. Ma, X. Dong, C.L. Swadley, A. Gupte, M. Leggas, H.C. Ledebur, and R.J. Mumper Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia J. Biomed. Nanotechnol. 5 2009 151 161
15. H. Maeda, G.Y. Bharate, and J. Daruwalla Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect Eur. J. Pharm. Biopharm. 71 2009 409 419
16. K. Mahéo, S. Vibet, J.P. Steghens, C. Dartigeas, M. Lehman, P. Bougnoux, and J. Goré Differential sensitization of cancer cells to doxorubicin by DHA: a role for lipoperoxidation Free Radical Biol. Med. 39 2005 742 751
17. W. Mehnert, and K. Mäder Solid lipid nanoparticles: production, characterization and applications Adv. Drug Deliv. Rev. 47 2001 165 196
18. A. Miglietta, R. Cavalli, C. Bocca, L. Gabriel, and M.R. Gasco Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel Int. J. Pharm. 210 2000 61 67
19. Milipore, United States of America, 1999. Passivation of Amicon Centricon Concentrators for Improved Recovery. Protocol Note. < http://www.millipore. com/techpublications/tech1/pc1003en00 >.
20. R.H. Müller, K. Mäder, and S. Gohla Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art Eur. J. Pharm. Biopharm. 50 2000 161 177
21. Y. Octavia, C.G. Tocchetti, K.L. Gabrielson, S. Janssens, H.J. Crijns, and A.L. Moens Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies J. Mol. Cell. Cardiol. 52 2012 1213 1225
22. S. Ozawa, Y. Sugiyama, Y. Mitsuhashi, T. Kobayashi, and M. Inaba Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product Cancer Chemother. Pharmacol. 21 1988 185 190
23. A.J. Primeau, A. Rendon, D. Hedley, L. Lilge, and I.F. Tannock The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors Clin. Cancer Res. 11 2005 8782 8788
24. K.M. Rosenblatt, and H. Bunjes Poly(vinyl alcohol) as emulsifier stabilizes solid triglyceride drug carrier nanoparticles in the alpha-modification Mol Pharm. 6 2009 105 120
25. L. Serpe, M.G. Satalano, R. Cavalli, E. Ugazio, O. Bosco, R. Canaparo, E. Muntoni, R. Frairia, M.R. Gasco, M. Eandi, and G.P. Zara Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line Eur. J. Pharm. Biopharm. 58 2004 673 680
26. R.A. Siddiqui, K.A. Harvey, Z. Xu, E.M. Bammerlin, C. Walker, and J.D. Altenburg Docosahexaenoic acid: a natural powerful adjuvant that improves efficacy for anticancer treatment with no adverse effects Biofactors 37 2011 399 412
27. A. Siddiqui, V. Gupta, Y. Liu, and S. Nazzal Doxorubicin and MBO-asGCS oligonucleotide loaded lipid nanoparticles overcome multidrug resistance in adriamycin resistant ovarian cancer cells (NCI/ADR-RES) Int. J. Pharm. 431 2012 222 229
28. R.K. Subedi, K.W. Kang, and H. Choi Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin Eur. J. Pharm. Sci. 37 2009 508 513
29. V. Torchilin Tumor delivery of macromolecular drugs based on the EPR effect Adv. Drug Deliv. Rev. 63 2011 131 135
30. O. Trédan, C.M. Galmarini, K. Patel, and I.F. Tannock Drug resistance and the solid tumor microenvironment J. Natl. Cancer Inst. 99 2007 1441 1454
31. S.A. Wissing, O. Kayser, and R.H. Müller Solid lipid nanoparticles for parenteral drug delivery Adv. Drug Deliv. Rev. 56 2004 1257 1272
32. H.L. Wong, R. Bendayan, A.M. Rauth, and X.Y. Wu Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers J. Pharm. Sci. 93 2004 1993 2004
33. H.L. Wong, A.M. Rauth, R. Bendayan, J.L. Manias, M. Ramaswamy, Z. Liu, S.Z. Erhan, and X.Y. Wu A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells Pharm. Res. 23 2006 1574 1585
34. H.L. Wong, R. Bendayan, A.M. Rauth, H.Y. Xue, K. Babakhanian, and X.Y. Wu A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system J. Pharmacol. Exp. Ther. 317 2006 1372 1381
35. H.L. Wong, A.M. Rauth, R. Bendayan, and X.Y. Wu In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model Eur. J. Pharm. Biopharm. 65 2007 300 308
36. Zara, G.P.; Cavalli, R.; Fundarò, A.; Bargoni, A.; Caputo, O.; Gasco, M.R. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN) Pharm Res. 40 1999 281 286
37. J.G. Zijlstra, E.G. de Vries, F.A. Muskiet, I.A. Martini, H. Timmer-Bosscha, and N.H. Mulder Influence of docosahexaenoic acid in vitro on intracellular adriamycin concentration in lymphocytes and human adriamycin-sensitive and-resistant small-cell lung cancer cell lines, and on cytotoxicity in the tumor cell lines Int. J. Cancer. 40 1987 850 856